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We have previously identiﬁed sole þ9, 13q- or 20q-, as
‘favorable’ and sole þ8 or complex karyotype as ‘unfavorable’
cytogenetic abnormalities in primary myeloﬁbrosis (PMF).
In this study of 433 PMF patients, we describe additional sole
abnormalities with favorable (chromosome 1 translocations/
duplications) or unfavorable ( 7/7q-) prognosis and also show
that other sole or two abnormalities that do not include i(17q),
 5/5q-, 12p-, inv(3) or 11q23 rearrangement are prognostically
aligned with normal karyotype, which is prognostically favor-
able. These ﬁndings were incorporated into a reﬁned two-tired
cytogenetic-risk stratiﬁcation: unfavorable and favorable karyo-
type. The respective 5-year survival rates were 8 and 51%
(hazard ratio (HR): 3.1, 95% conﬁdence interval (CI): 2.2–4.3;
Po0.0001). Multivariable analysis conﬁrmed the International
Prognostic Scoring System (IPSS)-independent prognostic
value of cytogenetic-risk categorization and also identiﬁed
thrombocytopenia (platelets o100 10
9/l) as another indepen-
dent predictor of inferior survival (Po0.0001). A similar multi-
variable analysis showed that karyotype (P¼0.001) and platelet
count (P¼0.04), but not IPSS (P¼0.27), predicted leukemia-free
survival; the 5-year leukemic transformation rates for unfavor-
able versus favorable karyotype were 46 and 7% (HR: 5.5, 95%
CI: 2.5–12.0; Po0.0001). This study provides the rationale and
necessary details for incorporating cytogenetic ﬁndings and
platelet count in future prognostic models for PMF.
Leukemia (2011) 25, 82–88; doi:10.1038/leu.2010.234;
published online 14 October 2010
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Introduction
Current drug therapy for primary myeloﬁbrosis (PMF) has not
been shown to prolong survival. Therefore, an increasing
number of patients are considering either allogeneic stem cell
transplantation (allo-SCT) or participation in experimental drug
treatment trials.
1–5 Allo-SCT is potentially curative in PMF, but
its utility is limited by the relatively high incidence of treatment-
related mortality and morbidity. The long-term toxicity proﬁle of
new drugs is unknown and they are not necessarily less risky
than allo-SCT.
2 In general, it is reasonable to justify the risk
of either allo-SCT or experimental drug therapy for PMF in the
presence of a o5 years life expectancy or 420% 5-year risk of
developing acute leukemia.
6 Accordingly, accurate prediction
of both shortened survival and leukemic transformation is an
essential component of the overall therapeutic decision-making
process.
7
The International Prognostic Scoring System (IPSS) for PMF is
used to predict survival.
8 The IPSS uses ﬁve independent
predictors of inferior survival: age 465 years, hemoglobin
o10g/100ml, leukocyte count 425 10
9/l, circulating blasts
X1% and constitutional symptoms.
8 The presence of 0, 1, 2 and
X3 adverse factors deﬁnes low, intermediate-1, intermediate-2
and high-risk disease with corresponding median survivals
of approximately 11.3, 7.9, 4 and 2.3 years.
8 A dynamic
prognostic model (DIPSS) that utilizes the same prognostic
variables but can be applied at any time during the disease
course was recently published.
9 DIPSS assigns two, instead of
one, adverse points for hemoglobin o10g/100ml and risk
categorization is accordingly modiﬁed: low (0 adverse points),
intermediate-1 (1 or 2 points), intermediate-2 (3 or 4 points) and
high (5 or 6 points). The corresponding median survivals were
not reached, 14.2, 4 and 1.5 years. Neither IPSS nor DIPSS
considers cytogenetic ﬁndings in its prognostic model.
Approximately, one-third of patients with PMF present with
abnormal karyotype, whose prognostic value was revisited in
three recent studies, each comprising 202,
10 200
11 and 131
12
patients evaluated at or within 1 year of diagnosis. All three
studies conﬁrmed the previously reported
13 favorable prognostic
impact of sole 20q- or sole 13q-. In addition, two of the three
studies identiﬁed sole þ9 as another favorable cytogenetic
marker.
11,12 The list of unfavorable cytogenetic abnormalities
from these and other related studies includes complex karyotype
(X3 abnormalities), sole þ8 and an abnormal karyotype that
includes abnormalities of chromosomes 5, 7, 17 or 12p-.
10–14
The purpose of this study, which includes more than twice the
number of patients included in previous studies,
10–12 was to
identify additional prognostically relevant cytogenetic abnorm-
alities in PMF and reﬁne cytogenetic-risk categorization for
overall and leukemia-free survival.
Materials and methods
This study was approved by the Mayo Clinic Institutional
Review Board. Clinical and laboratory data were collected from
consecutive patients with PMF seen at our institution and in
whom cytogenetic information at or within 1 year of diagnosis
was available. The diagnoses of PMF and leukemic transforma-
tion were according to the 2001 World Health Organization
criteria.
15 Bone marrow chromosome and JAK2V617F mutation
analysis were performed according to previously published
methods.
16,17 Cytogenetic results were interpreted and
reported according to the International System for Human
Cytogenetic Nomenclature; abnormal karyotype was deﬁned by
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www.nature.com/leuthe presence of at least two metaphases with structural
abnormalities or monosomy or three metaphases with polysomy,
regardless of number of metaphases examined.
18 In order to be
consistent with methodology used in recent studies,
11,12 the
presence of o20 evaluable metaphases did not disqualify
patients from study inclusion as long as X10 metaphases were
examined in those patients with ‘normal’ reports.
In order to examine the prognostic impact of speciﬁc
cytogenetic abnormalities, initial cytogenetic group assignment
required the presence of at least ﬁve informative cases.
11 Sole
cytogenetic abnormalities occurring in less than ﬁve patients
were grouped together and classiﬁed into two separate
operational subgroups: ‘other high-risk’ and ‘other indetermi-
nate-risk’ sole abnormalities. Assignment to the ‘other high-risk’
category was based on previously published observations on the
prognostic impact of a particular cytogenetic abnormality in
PMF and the sole abnormalities in this regard included  5/5q-,
i(17q), 12p-, 11q23 rearrangement and inv(3).
10–14 All other
sole abnormalities that did not meet the threshold criteria of ﬁve
informative cases were grouped together as ‘indeterminate-risk
sole abnormalities’. Patients with two cytogenetic abnormalities
were also classiﬁed into two ‘high-risk’ and ‘indeterminate-risk’
subgroups based on the presence or absence of an unfavorable
abnormality including þ8,  7/7q-,  5/5q-, i(17q), 12p-, inv(3)
or 11q23 rearrangement.
All statistical analyses considered parameters at diagnosis
and before the initiation of speciﬁc therapy. Differences in the
distribution of continuous variables between categories were
analyzed by either Mann–Whitney (for comparison of two
groups) or Kruskal–Wallis (comparison of three or more groups)
test. Patient groups with nominal variables were compared by w
2
test. Overall survival analysis was considered from the date of
diagnosis to date of death (uncensored) or last contact
(censored). Leukemia-free survival was calculated from the date
of diagnosis to date of leukemic transformation (uncensored) or
last contact/date of death (censored). Additional analyses that
censored patients at time of allo-SCT were performed for both
overall and leukemia-free survival in order to avoid possible
confounding of survival effect from the particular treatment
modality. Overall and leukemia-free survival curves were
prepared by the Kaplan–Meier method and compared by the
log-rank test. Cox proportional hazard regression model was
used for multivariable analysis. P-values o0.05 were consi-
dered signiﬁcant. The Stat View (SAS Institute, Cary, NC, USA)
statistical package was used for all calculations.
Results
A total of 433 patients with PMF, which included the 200
patients from our previous report,
11 constituted this study
population; presenting clinical and laboratory features are
outlined in Table 1. Dates of diagnosis spanned from January
1978 to November 2009. Median age at diagnosis was 65 years
(range 14–92) and 268 (62%) were males. The IPSS-risk
distributions could be accurately assigned for 384 patients:
low in 46 (12%) patients, intermediate-1 in 97 (25%),
intermediate-2 in 93 (24%) and high in 148 (39%). Twenty-six
percent of the patients presented with thrombocytopenia
(platelets o100 10
9/l) and 17% with leukopenia (leukocytes
o4 10
9/l). JAK2V617F mutation analysis was performed in
174 patients and mutational frequency was 60%.
At the time of this report, 269 (62%) patients had died and
median follow-up of patients who were alive was approximately
4 years. During this period, 34 (8%) cases of leukemic
transformation were documented. As expected, the IPSS
13
effectively delineated patient groups with different prognosis
(Figure 1); median survivals in low, intermediate-1, intermedi-
ate-2 and high IPSS-risk categories were 15, 7, 3.6 and 2.2
years, respectively (Po0.0001). The corresponding 5-year
survival rates were 85, 65, 40 and 19% with hazard ratios
(HRs) (95% conﬁdence interval (CI)) of 7.7 (4.4–13.6;
Po0.0001), 4.0 (2.2–7.1; Po0.001), 2.0 (1.1–3.6; P¼0.02)
for high, intermediate-2 and intermediate-1-risk groups,
respectively.
Treatment received during disease course was markedly
heterogeneous and mostly pursued for palliative purposes; 57
(14%) cases of splenectomy and 17 (4%) of allo-SCT were
documented, whereas the spectrum of drugs used included
hydroxyurea, androgens, danazol, erythropoiesis stimulating
agents, prednisone, thalidomide, lenalidomide, interferon,
anagrelide, busulfan and experimental agents. As most deaths
occurred elsewhere, cause of death was not accurately
documented in most instances, but when known, included
leukemic transformation (n¼28), infection (n¼22), ‘progressive
disease’ (n¼10), intracerebellar/intracranial bleed (n¼5), heart
failure (n¼5), non-infectious respiratory failure (n¼5), other
malignancies (n¼5), myocardial infarction or cardiac arrest
(n¼4), stroke (n¼3), gastrointestinal bleeding (n¼3), intra-
abdominal bleeding (n¼3), hepatic failure (n¼3), complica-
tions of allo-SCT (n¼2), pancreatitis (n¼1), disseminated
intravascular coagulopathy (n¼1) and motor vehicle accident
(n¼1).
Cytogenetic details at presentation
Cytogenetic ﬁndings were normal in 275 (64%) patients. Among
the 158 (36%) patients with abnormal karyotype, 109 (69% of
abnormal cases) represented sole abnormalities, 23 (15%) two
abnormalities and 26 (17%) three or more (that is complex)
abnormalities. The most frequent sole abnormality was 20q-
constituting 28% (n¼30) of all sole abnormalities, 19% of all
abnormal cases and 7% of the entire study cohort (Table 1).
Other sole abnormalities that met the threshold criteria of ﬁve
informative cases, for consideration as a separate cytogenetic
category, included þ8( n¼14), 13q- (n¼10), chromosome 1
translocation/duplication (n¼12), þ9( n¼9) and  7/7q-
(n¼5).
Twenty-nine patients had sole abnormalities that were each
seen in less than ﬁve patients; these cases were classiﬁed into
two separate groups for further analysis, as elaborated in
Materials and methods: ‘other high-risk sole abnormalities’
(n¼6) and ‘other indeterminate-risk sole abnormalities’
(n¼23). The former included i(17q),  5/5q-, 12p-, 11q23
rearrangement or inv(3) and the latter as outlined in the footnote
of Table 1. Twenty-three patients had two abnormalities that did
(n¼8) or did not (n¼15) include known or putative unfavor-
able abnormalities including þ8,  7/7q-, i(17q),  5/5q-, 12p-,
11q23 rearrangement or inv(3). In other words, as was
previously outlined in the context of ‘other’ sole abnormalities,
patients with two cytogenetic abnormalities were sub-classiﬁed
into two separate groups for further analysis.
Comparison of clinical characteristics among
cytogenetic categories
Based on the above, 12 cytogenetic categories were initially
considered and compared for their presenting clinical and
laboratory features (Table 1). Signiﬁcant differences were noted
in regards to platelet count considered as a continuous variable
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Leukemia(Po0.0001), thrombocytopenia (platelet count o100 10
9/l;
P¼0.0001) and leukopenia (leukocyte count o4 10
9/l;
Po0.0001) (Table 1). These differences were also evident when
analysis was restricted to patients with favorable karyotype; the
incidences of leukopenia and thrombocytopenia were highest
in patients with sole 20q- (41 and 38%, respectively) and lowest
in those with sole 13q- (0 and 0%, respectively) (Table 1).
Establishment of a two-tired cytogenetic-risk
stratiﬁcation
In an effort to identify cytogenetic categories of similar
prognosis, each one of the above-discussed 12 cytogenetic
categories was separately compared with both normal and
complex karyotype.
The survival of patients with sole 13q-, sole 20q-, sole þ9,
sole chromosome 1 translocation/duplication, ‘other sole
abnormalities of indeterminate-risk’ or ‘two abnormalities
excluding an unfavorable type’ was similar to that of patients
with normal karyotype (P-value of 0.07, 0.96, 0.91, 0.46,
0.3 and 0.3, respectively; Figure 2) and signiﬁcantly superior to
that of patients with complex karyotype (P-value of o0.0001,
o0.0001, 0.01, 0.0001, 0.0002 and 0.02, respectively;
Figure 2). These cytogenetic subcategories were, therefore,
grouped together with normal karyotype and assigned a
‘favorable karyotype’ prognostic category (Table 2). Of note,
the borderline P-value of 0.07 for survival comparison of normal
karyotype and 13q- was in favor of the latter.
The survival of patients with sole þ8, sole  7/7q-, ‘other
high-risk sole abnormalities’ or ‘two abnormalities including an
unfavorable type’ was similar to that of patients with complex
karyotype (P-value of 0.30, 0.84, 0.74 and 0.14, respectively;
Figure 2). These cytogenetic categories were accordingly
grouped together with complex karyotype and assigned an
‘unfavorable karyotype’ prognostic category (Table 2).
Table 2 compares the clinical presentation of the above-
deﬁned ‘favorable’ and ‘unfavorable’ cytogenetic-risk groups.
Unfavorable karyotype was associated with thrombocytopenia
(platelet count o100 10
9/l; Po0.0001), leukopenia (leuko-
cyte count o4 10
9/l; P¼0.0004), circulating blasts X1%
(P¼0.003), lower hemoglobin level (P¼0.003) and high-risk
IPSS score (P¼0.01). These ﬁndings support the need for
multivariable analysis in deciphering the IPSS-independent prog-
nostic value of cytogenetic-risk categorization. Males were over-
represented in the favorable karyotype group, but the explanation
for this observation is not immediately clear (64%; P¼0.01).
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Figure 1 Survival data of patients with primary myeloﬁbrosis stratiﬁed by the International Prognostic Scoring System.
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sole 20q-; n=30
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normal karyotype; n=275
UNFAVORABLE:
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sole +8; n=14
sole -7/7q-; n=5
sole -5/5q-, i(17q), inv(3), 12p-or 11q23 abnormality; n=6
two abnormalities including unfavorable type; n=8
Figure 2 Survival data of patients with primary myeloﬁbrosis stratiﬁed by speciﬁc cytogenetic categories.
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LeukemiaComparison of overall and leukemia-free survival
between favorable and unfavorable karyotype
Median survivals of patients with favorable and unfavorable
karyotype were 5.2 and 2.0 years, respectively (Po0.0001;
Figure 3). The corresponding 5-year survival rates were 51 and
8% (HR: 3.1, 95% CI: 2.2–4.3; Po0.0001). Multivariable
analysis, which included variables that were found to
be signiﬁcant in univariate analysis (Table 2), conﬁrmed
the IPSS-independent prognostic value of cytogenetic-risk
categorization (Po0.0001; HR: 2.1, 95% CI: 1.5–3.1) and also
identiﬁed thrombocytopenia (platelet count o100 10
9/l) as
another independent predictor of inferior survival (Po0.0001;
HR: 1.9, 95% CI: 1.4–2.6); the HRs (95% CI) for IPSS high-risk,
intermediate-2 and intermediate-1-risk groups were 6.4
(3.6–11.3), 3.7 (2.0–6.7) and 1.9 (1.1–3.4), respectively
(Po0.0001). A similar multivariable analysis showed that
cytogenetic-risk proﬁle (P¼0.001; HR: 4.1, 95% CI: 1.7–9.6)
and platelet count (P¼0.04; HR: 2.3, 95% CI: 1.0–5.0), but not
Table 2 Cytogenetic-risk groups of 433 patients with primary myeloﬁbrosis
Variables All patients
(n¼433)
Favorable karyotype
(n¼374)
a
Unfavorable karyotype
(n¼59)
b
P-value
Age (years), median (range) 65 (14–92) 65 (14–87) 66 (15–92) 0.23
Age 4 65 years, n (%) 206 (48) 174 (47) 32 (54) 0.27
Males (%) 268 (62) 240 (64) 28 (47) 0.01
Hemoglobin, g/100ml, median (range) 10.2 (5–16.1) 10.3 (5–16.1) 9.8 (6.3–12.9) 0.003
Leukocyte count 10
9/l, median (range) 8.3 (0.9–113.2) 8.3 (0.9–113.2) 6.3 (1.5–69.2) 0.08
Platelet count 10
9/l, median (range) 229 (6–1765) 246 (11–1765) 99 (6–968) o0.0001
IPSS risk group (%) n evaluable¼384 0.01
Low 12 13 2
Intermediate-1 25 26 23
Intermediate-2 24 25 19
High 39 36 56
Constitutional symptoms, n (%), n evaluable¼418 150 (36) 124 (34) 26 (46) 0.07
Circulating blasts X1%, n (%), n evaluable¼386 211 (55) 172 (52) 39 (74) 0.003
Hemoglobin o10g/100ml, n (%) 222 (52) 184 (50) 38 (66) 0.02
Leukocytes 425 10
9/l, n (%) 58 (14) 50 (13) 8 (14) 0.94
Platelets o100 10
9/l, n (%) 110 (26) 80 (22) 30 (52) o0.0001
Leukocytes o4 10
9/l, n (%) 71 (17) 52 (14) 19 (33) 0.0004
Splenectomy, n (%) 57 (14) 49 (14) 8 (15) 0.85
JAK2V617F status n tested (% positive) 174 (60) 160 (59) 14 (71) 0.37
Transplanted, n (%) 17 (4) 13 (4) 4 (7) 0.2
Deaths, n (%) 269 (62) 220 (59) 49 (83) 0.0004
Leukemic transformations, n (%) 34 (8) 24 (6) 10 (17) 0.005
Abbreviation: IPSS, International Prognostic Scoring System.
8
aFavorable karyotype: normal karyotype or sole or two abnormalities that do not include the above-listed unfavorable cytogenetic abnormalities.
bUnfavorable karyotype: complex karyotype or sole or two abnormalities that include +8,  7/7q-, i(17q),  5/5q-, 12p-, inv(3) or 11q23
rearrangement.
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Figure 3 Survival data of patients with primary myeloﬁbrosis stratiﬁed by two-tired cytogenetic-risk categorization: unfavorable (complex
karyotype or sole or two abnormalities that include þ8,  7/7q-, i(17q), inv(3),  5/5q-, 12p- or 11q23 rearrangement) and favorable (all other
scenarios including normal karyotype).
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LeukemiaIPSS (P¼0.27), predicted leukemia-free survival; the 5-year
leukemic transformation rates for unfavorable and favorable
karyotype were 46 and 7%, respectively (HR: 5.5, 95% CI:
2.5–12.0; Po0.0001). These results, in terms of both overall and
leukemia-free survival analysis, did not change when patients
receiving allo-SCT were censored at the time of their transplant.
Discussion
Recent studies have been mostly consistent in their report on the
prognostic value of cytogenetic ﬁndings in PMF.
10–12 There is
now a general agreement on the favorable prognostic impact
of normal karyotype and sole abnormalities of 20q-, 13q- and
þ9. All other abnormalities were usually lumped together and
prognostically considered as being unfavorable.
10,19 It is
reasonable to assume that this latter group includes prognos-
tically diverse cytogenetic abnormalities and their identiﬁcation
as such should enable further reﬁnement of cytogenetic-risk
categorization in PMF. It is also important to determine
the prognostic impact of both cytogenetic-risk categorization
and IPSS on leukemia-free survival.
In our previous report of 200 patients with PMF,
11 there were
adequate numbers of informative cases that enabled us to
individually associate normal karyotype (n¼117) or sole
abnormalities of 20q- (n¼21), 13q- (n¼8) or þ9( n¼6) with
favorable survival and complex karyotype (n¼13) or sole þ8
(n¼7) with unfavorable survival. This is now conﬁrmed by this
study of 433 PMF patients, which features a higher number of
cases in each of these cytogenetic categories: normal karyotype
(n¼275), sole 20q- (n¼30), sole 13q- (n¼10), sole þ9( n¼9),
sole þ8( n¼14) and complex karyotype (n¼26). What is new
in this study was the fact that we had sufﬁcient numbers of
patients with sole abnormalities of chromosome 1 including
translocation/duplication (n¼12) and  7/7q- (n¼5) to examine
their individual impact on survival and label the former as being
prognostically favorable and the latter unfavorable. Of note,
this particular observation is inconsistent with a previously
published study from Japan, which had suggested a similar
survival between patients with  7/7q- and normal karyotype.
10
Also new in this study was our successful strategy to
distinguish two prognostically different groups of patients with
other sole abnormalities that did not meet the threshold number
(that is X5 informative cases) for individual assessment of
prognostic impact. As outlined in Materials and methods, these
were operationally categorized into ‘other high-risk’ and ‘other
indeterminate-risk’ subgroups of sole abnormalities based on
putative prognostic relevance derived from previously published
observations.
10–14 The former included sole abnormalities of
i(17q),  5/5q-, 12p-, 11q23 rearrangement or inv(3) and we
show that the survival of patients with any one of these
abnormalities was signiﬁcantly inferior to that of patients with
normal karyotype and similar to that of patients with complex
karyotype, sole þ8 or sole  7/7q-. In contrast, the survival of
patients with other sole abnormalities that did not include þ8,
 7/7q-, i(17q),  5/5q-, 12p-, 11q23 rearrangement or inv(3)
was similar to that of patients with normal karyotype and
signiﬁcantly superior to that of patients with complex karyotype.
The same was true for patients with two abnormalities whose
survival was aligned with either complex or normal karyotype
depending on the presence or absence of the above-mentioned
unfavorable cytogenetic abnormalities. A previous study had
similarly suggested a negative prognostic impact for abnormal-
ities of chromosomes 5, 7 and 17, but the particular observation
was confounded by the inclusion of complex karyotype and
cases with two abnormalities in the analysis.
12
Based on the above, we were able to devise a two-tired
cytogenetic-risk stratiﬁcation with highly signiﬁcant differences
in overall and leukemia-free survival (Figures 3 and 4):
unfavorable (complex karyotype or sole or two abnormalities
that include þ8,  7/7q-, i(17q), inv(3),  5/5q-, 12p- or 11q23
rearrangement) and favorable (all other cytogenetic ﬁndings
including normal karyotype). The prognostic relevance of
karyotype was independent of other previously established
predictors of overall (IPSS and thrombocytopenia)
8,20 and
leukemia-free (thrombocytopenia)
21,22 survival in PMF. In the
original IPSS report,
8 cytogenetic information was available in
409 patients and the presence of ‘abnormal’ karyotype was
signiﬁcantly associated with inferior survival.
8 Additional
cytogenetic details were not available to delineate the
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Figure 4 Leukemia-free survival data of patients with primary myeloﬁbrosis stratiﬁed by two-tired cytogenetic-risk categorization: unfavorable
(complex karyotype or sole or two abnormalities that include þ8,  7/7q-, i(17q), inv(3),  5/5q-, 12p- or 11q23 rearrangement) and favorable
(all other scenarios including normal karyotype).
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Leukemiaprognostic impact of speciﬁc cytogenetic categories and
leukemia-free survival analysis was not performed. In this study,
IPSS was not found to be predictive of leukemic transformation.
We instead found a platelet count of o100 10
9/l to be a
powerful and independent adverse factor for both overall and
leukemia-free survival. These observations strongly favor the
inclusion
of both cytogenetic information and presence or absence of
thrombocytopenia in future prognostic models for PMF. On the
other hand, additional studies are needed to validate recently
described molecular proﬁles of potential prognostic importance
before their formal consideration.
17,23–27
Finally, it was interesting to note a highly signiﬁcant
association between sole 20q- and both leukopenia and
thrombocytopenia. Such an association was not evident in
the other favorable cytogenetic categories and suggests a
20q- haploinsufﬁcient gene effect, which might also explain a
previously reported association between MDS with sole
20q- and thrombocytopenia.
28
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